Treats osteoporosis in postmenopausal women. ANDA 205332, held by Eugia Pharma. Ibandronate Sodium.
As of Nov 16, 2026, ANDA 205332 (Ibandronate Sodium), held by Eugia Pharma, was first approved by FDA on Aug 19, 2015, with 2 approved supplements and 0 published complete response letters.
Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use 1.1 Treatment of Postmenopausal Osteoporosis
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 3MG BASE/3ML · injectable;intravenous | Ibandronate Sodium | Rx |
| Feb 3, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 31, 2020 | Supplement 4Manufacturing | Approved | None posted |
| Aug 19, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters